TABLE 1.
MIC values for tedizolid and comparative antimicrobials against isolates of nontuberculous mycobacteria
Species (no. of isolates tested) | Intermediate breakpoint (μg/ml) | Antimicrobial agent | MIC (μg/ml) |
||
---|---|---|---|---|---|
Range | 50% | 90% | |||
Rapidly growing species | |||||
M. abscessus subsp. abscessus (81) | —a | Tedizolid | 0.12–>32 | 4 | 8 |
16 | Linezolid | 0.25–128 | 16 | 32 | |
32 | Amikacin | 2–>1024 | 16 | 32 | |
32–64 | Cefoxitin | 16–64 | 32 | 64 | |
2 | Ciprofloxacin | 0.5–>4 | >4 | >4 | |
4 | Clarithromycinb | 0.5–>16 | >16 | >16 | |
2–4 | Doxycycline | 8–>16 | >16 | >16 | |
8–16 | Imipenem | 4–>64 | 16 | 32 | |
2–4 | Minocycline | 2–>8 | >8 | >8 | |
2 | Moxifloxacin | 2–>8 | 8 | >8 | |
— | Tigecyclinec | 0.03–0.5 | 0.25 | 0.5 | |
— | TMP-SMXd | ≤0.25/4.75–8/152 | 4/76 | 8/152 | |
M. abscessus subsp. massiliense (12) | — | Tedizolid | 0.12–>32 | 2 | 4 |
16 | Linezolid | 0.5–32 | 8 | 32 | |
32 | Amikacin | 4–>1024 | 16 | 64 | |
32–64 | Cefoxitin | 32–64 | 32 | 64 | |
2 | Ciprofloxacin | 1–>4 | 4 | 4 | |
4 | Clarithromycinb | 0.12–>128 | 0.5 | 2 | |
2–4 | Doxycycline | 0.25–>16 | >16 | >16 | |
8–16 | Imipenem | 8–32 | 8 | 16 | |
2–4 | Minocycline | ≤1–>8 | >8 | >8 | |
2 | Moxifloxacin | 2–>8 | 8 | >8 | |
— | Tigecyclinec | 0.06–0.5 | 0.25 | 0.5 | |
— | TMP-SMXd | 4/76–>8/152 | 4/76 | >8/152 | |
M. abscessus subsp. massiliense/M. abscessus subsp. abscessus hybride (6) | — | Tedizolid | 0.25–>32 | 0.5 | |
16 | Linezolid | 2–>128 | 16 | ||
32 | Amikacin | 16–64 | 16 | ||
32–64 | Cefoxitin | 16–64 | 32 | ||
2 | Ciprofloxacin | 4–>4 | 4 | ||
4 | Clarithromycina | 0.12–16 | 1 | ||
2–4 | Doxycycline | >16 | >16 | ||
8–16 | Imipenem | 8–16 | 16 | ||
2–4 | Minocycline | >8 | >8 | ||
2 | Moxifloxacin | 4–>8 | 4 | ||
— | Tigecyclinec | 0.12–0.25 | 0.12 | ||
— | TMP-SMXd | 2/38–8/152 | 4/76 | ||
M. chelonae (22) | — | Tedizolid | 0.25–4 | 1 | 2 |
16 | Linezolid | 2–16 | 8 | 16 | |
32 | Amikacin | 8–32 | 16 | 32 | |
32–64 | Cefoxitin | 128–>128 | >128 | >128 | |
2 | Ciprofloxacin | 0.5–>4 | 4 | >4 | |
4 | Clarithromycina | ≤0.06–>128 | 1 | 2 | |
2–4 | Doxycycline | 2–>16 | >16 | >16 | |
8–16 | Imipenem | 8–64 | 16 | 32 | |
2–4 | Minocycline | ≤1–>8 | >8 | >8 | |
2 | Moxifloxacin | 1–>8 | 4 | 8 | |
— | Tigecyclinec | 0.06–0.5 | 0.25 | 0.5 | |
— | Tobramycin | ≤1–2 | 2 | 2 | |
— | TMP-SMXd | 1/19–>8/152 | 4/76 | >8/152 | |
M. mucogenicum group (9) | — | Tedizolid | 0.06–4 | 1 | |
16 | Linezolid | 0.5–8 | 1 | ||
32 | Amikacin | ≤0.5–4 | 1 | ||
32–64 | Cefoxitin | 4–16 | 16 | ||
2 | Ciprofloxacin | 0.25–>4 | 0.5 | ||
4 | Clarithromycina | 0.25–2 | 1 | ||
2–4 | Doxycycline | 0.25–>16 | 16 | ||
8–16 | Imipenem | ≤2 | ≤2 | ||
2–4 | Minocycline | 1–>8 | >8 | ||
2 | Moxifloxacin | ≤0.12–2 | 0.5 | ||
— | Tigecyclinec | 0.03–0.25 | 0.25 | ||
— | TMP-SMXd | ≤0.25/4.75–0.5/9.5 | ≤0.25/4.75 | ||
M. immunogenum (9) | — | Tedizolid | 0.5–4 | 1 | |
16 | Linezolid | 0.12–16 | 8 | ||
32 | Amikacin | 8–16 | 8 | ||
32–64 | Cefoxitin | 8–>128 | >128 | ||
2 | Ciprofloxacin | 2–>4 | 4 | ||
4 | Clarithromycina | 0.5–2 | 2 | ||
2–4 | Doxycycline | >16 | >16 | ||
8–16 | Imipenem | 16–64 | 16 | ||
2–4 | Minocycline | >8 | >8 | ||
2 | Moxifloxacin | 1–>8 | 8 | ||
— | Tigecyclinec | 0.06–0.5 | 0.25 | ||
— | Tobramycin | 4–16 | 16 | ||
— | TMP-SMXd | 4/76–>8/152 | 8/152 | ||
M. fortuitum (20) | — | Tedizolid | 0.25–2 | 1 | 2 |
16 | Linezolid | 1–8 | 2 | 4 | |
32 | Amikacin | ≤1 | ≤1 | ≤1 | |
32–64 | Cefoxitin | 8–64 | 32 | 64 | |
2 | Ciprofloxacin | ≤0.12–0.25 | ≤0.12 | ≤0.12 | |
4 | Clarithromycina | ≤0.06–128 | 32 | 64 | |
2–4 | Doxycycline | ≤0.12–>16 | 0.5 | >16 | |
8–16 | Imipenem | ≤2–4 | 4 | 4 | |
2–4 | Minocycline | ≤1–>8 | ≤1 | >8 | |
2 | Moxifloxacin | ≤0.25 | ≤0.25 | ≤0.25 | |
— | Tigecyclinec | 0.03–0.5 | 0.12 | 0.25 | |
— | TMP-SMXd | ≤0.25/4.75–2/38 | 0.5/9.5 | 1/19 | |
Slowly growing species | |||||
M. avium complex (100) | — | Tedizolid | 1–>32 | 8 | >32 |
16 | Linezolid | 2–128 | 32 | 64 | |
— | Amikacinf | 2–>1024 | 32 | 128 | |
16 | Clarithromycin | 0.25–>128 | 2 | 8 | |
2 | Moxifloxacin | 0.25–>8 | 4 | 8 | |
M. arupense (9) | — | Tedizolid | 1–4 | 4 | |
16 | Linezolid | 8–32 | 16 | ||
32 | Amikacin | 32–>1024 | 64 | ||
2 | Ciprofloxacin | 16–>16 | >16 | ||
16 | Clarithromycin | 0.25–1 | 0.5 | ||
4 | Doxycycline | 4–>16 | 1 | ||
4 | Ethambutol | ≤0.5–8 | >16 | ||
2 | Moxifloxacin | >8 | >8 | ||
2 | Rifabutin | ≤0.25–1 | ≤0.25 | ||
2 | Rifampin | 2–>8 | 8 | ||
— | TMP-SMXd | 0.5/9/5–4/76 | 2/38 | ||
M. kansasii (7) | — | Tedizolid | 0.25–1 | 0.5 | |
16 | Linezolid | 0.5–2 | 2 | ||
32 | Amikacin | 2–64 | 8 | ||
2 | Ciprofloxacin | 1–>16 | 2 | ||
16 | Clarithromycin | ≤0.06–1 | 0.25 | ||
4 | Doxycycline | 2–>16 | 16 | ||
4 | Ethambutol | 2–8 | 4 | ||
2 | Moxifloxacin | ≤0.12–0.5 | 0.25 | ||
2 | Rifabutin | ≤0.25–0.5 | ≤0.25 | ||
2 | Rifampin | ≤0.12–4 | 0.25 | ||
— | TMP-SMXd | ≤0.12/2.38–0.5/9.5 | ≤0.12/2.38 | ||
M. simiae (8) | — | Tedizolid | 1–>32 | 8 | |
16 | Linezolid | 8–128 | 64 | ||
32 | Amikacin | 32–128 | 32 | ||
2 | Ciprofloxacin | 16–>16 | 16 | ||
16 | Clarithromycin | 8–>64 | 8 | ||
4 | Doxycycline | >16 | >16 | ||
4 | Ethambutol | 16–>16 | >16 | ||
2 | Moxifloxacin | 4–>8 | 4 | ||
2 | Rifabutin | 8–>8 | >8 | ||
2 | Rifampin | >8 | >8 | ||
— | TMP-SMXd | 1/19–4/76 | 2/38 | ||
M. marinum (7) | — | Tedizolid | 0.25–1 | 1 | |
16 | Linezolid | 1–4 | 1 | ||
32 | Amikacin | ≤1–4 | ≤1 | ||
2 | Ciprofloxacin | 4–16 | 8 | ||
16 | Clarithromycin | 0.25–1 | 0.5 | ||
4 | Doxycycline | 2–8 | 2 | ||
4 | Ethambutol | ≤0.5–4 | 4 | ||
2 | Moxifloxacin | 0.5–8 | 1 | ||
2 | Rifabutin | ≤0.25 | ≤0.25 | ||
2 | Rifampin | ≤0.12–1 | 0.5 | ||
— | TMP-SMXd | 0.5/9.5–2/38 | 1/19 |
—, not determined.
Clarithromycin MIC is the result of extended incubation (up to 14 days) to detect macrolide resistance induced by the erm gene.
There is currently no CLSI-recommended breakpoint for tigecycline.
TMP-SMX, trimethoprim sulfamethoxazole. There is no intermediate breakpoint for TMP-SMX; resistance is ≥4/76 μg/ml.
There is currently no CLSI-recommended amikacin breakpoint for M. avium complex. A proposed resistance breakpoint associated with a 16S rRNA gene mutation (1408A→C) is >64 μg/ml (11).
M. abscessus subsp. massiliense by erm/M. abscessus subsp. abscessus by rpoB gene (a “hybrid” subspecies or may represent a new species).